Catalent

Catalent is a US-based company that provides differentiated development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products. The company works with pharma, biotech, and consumer health companies to optimize those companies' product development, launch, and full life-cycle supply globally. Catalent has expertise in development sciences, delivery technologies, and multi-modality manufacturing, helping companies with personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent Corporate Overview (2021)

Catalent is an S&P 500® company that is publicly traded on the New York Stock Exchange under the symbol CTLT. Alessandro Maselli was appointed as president and CEO in July 2022. The company is headquartered in Somerset, New Jersey and reported $4 billion in revenue in its 2021 fiscal year. Catalent has over 17,000 employees worldwide, which includes more than 2,500 scientists and technicians.

Notable customers include AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Moderna, Pfizer, and Pierre Fabre.Each year, Catalent helps accelerate over 1,000 partner programs and launch over 150 new products. Its flexible manufacturing platforms at over fifty sites across four continents supply more than 70 billion doses of nearly 7,000 products to over 1,000 customers annually.